[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anxiety-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anxiety-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,101,0,25,[9,48,62,93,119,153,191,214,236,266,297,320,344,371,401,427,447,471,496,525,548,574,602,632,653],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054265",false,"NCT00018057","Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders","* INCLUSION CRITERIA:\n\nALL JUVENILE SUBJECTS\n\n* Age: 8-17 (subjects who consent as 17-year-olds but turn 18 during the course of the study will be eligible to complete all procedures completed by other subjects who consent as 17-year-olds but do not turn 18).\n* Consent: can give consent\u002Fassent (Parents will provide consent; minors will provide assent)\n* IQ: all subjects will have IQ\\>70 (Assessment relies on either a WASI or assessment by trained clinical staff during the subject s screening visit. Completion of required activities during the screening visit requires an IQ above 70.)\n* Language: all subjects will speak English (Tasks in this protocol have not been validated in languages other than English)\n\nALL ADULT SUBJECTS\n\n* Age: 18-65\n* Consent: can give consent\n* IQ: all subjects will have IQ\\>70 (Assessment relies on either a WASI or assessment by trained clinical staff during the subject s screening visit. Completion of required activities during the screening visit requires an IQ above 70.)\n* Language: all subjects will speak English (Tasks in this protocol have not been validated in languages other than English)\n\nALL SUBJECTS WITH AN ANXIETY DISORDER\n\n* Diagnosis: Current Diagnosis of OCD, Social Phobia, Separation Anxiety, Generalized Anxiety Disorder, or Panic Disorder (Based on K-SADS (juveniles) or SCID (adults))\n* Symptom Severity: Clinically significant, ongoing anxiety symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n* Clinical Impairment: Clinically significant, ongoing distress or impairment from anxiety (This will be documented by clinician review with patients and their families during at least two visits with families.)\n\nALL PREVIOUSLY ENROLLED ADOLESCENT PATIENTS, CHILD AND ADULT HEALTHY VOLUNTEERS, AND ALL HEALTHY VOLUNTEERS TURNED PATIENTS\n\n* Diagnosis: Current Diagnosis of OCD, Social Phobia, Separation Anxiety, Generalized Anxiety Disorder, or Panic Disorder; No current diagnosis (Based on K-SADS (juveniles) or SCID (adults))\n* Clinical Impairment (as applicable): Clinically significant, ongoing symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n* Symptom Severity (as applicable): Clinically significant, ongoing symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n\nEXCLUSION CRITERIA:\n\nALL SUBJECTS\n\n* Any serious medical condition or condition that interferes with fMRI or M\u002FEEG scanning, and for patients electing medication, any condition that increases risk of SSRI treatment. (All patients will complete a medical history. Healthy volunteer participants will be medication- free and have no current serious medical conditions, based on a review of their medical history. Subjects only will be excluded from the MRI portions of the study based on this exclusion criterion.)\n* Pregnancy (Subjects only will be excluded from the MRI portions of the study based on this exclusion criterion.)\n* Current use of any psychoactive substance; current suicidal ideation as indicated by the presence of intent for engaging in suicidal behaviors; current diagnosis of attention deficit hyperactivity disorder (ADHD) of sufficient severity to require pharmacotherapy. (These factors could complicate treatment with an SSRI. No subject on medication will be accepted into the trial. Subjects will not be taken off of medications to enter the trial.)\n* Current diagnoses, major depressive disorder (MDD), post-traumatic distress disorder, conduct disorder. (These factors may be affected by SSRI treatment, influencing ability to detect effects on anxiety\u002Fsymptoms of depression. Of note, subjects who present with a diagnosis of MDD will not be eligible for inclusion at the outset of the study. However, youth with anxiety disorders frequently develop MDD when followed over time. Subjects will be allowed to remain in the study if they develop these diagnoses after enrollment.)\n* Past or current history of mania, psychosis, or severe pervasive developmental disorder. (These factors may be affected by SSRI treatment, influencing ability to detect effects on anxiety\u002Fsymptoms of depression. Of note, subjects who present with a diagnosis of MDD will not be eligible for inclusion at the outset of the study. However, youth with anxiety disorders frequently develop MDD when followed over time. Subjects will be allowed to remain in the study if they develop these diagnoses after enrollment.)\n* Recent use of an SSRI with failure to respond or tolerate SSRI treatment at an adequate dose and duration. (This is designed to exclude subjects who have failed a trial of an SSRI for their current problem with anxiety. For previously enrolled participants, including patients and healthy volunteers, current use of an SSRI does not exclude participation from follow-up research tasks.)\n* History of any (excepting nicotine-related and cannabis-related) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence).\n\nHEALTHY ADULT SUBJECTS\n\n-Any current psychiatric diagnosis (Assessment relies on SCID)",true,"ALL","8 Years","65 Years",{"count":20,"type":21},3500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Study Description:\n\nThis study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M\u002FEEG). Patients will be studied over one year, before and after receiving either one of two standard-of-care treatments: cognitive behavioral therapy (CBT) or fluoxetine, a serotonin reuptake inhibitor (SSRI). Healthy comparisons will be studied at comparable time points.\n\nPrimary Objectives:\n\nTo compare healthy youth and symptomatic, medication-free pediatric patients studied prior to receipt of treatment. The study seeks to detect relations between clinical features of anxiety disorders at baseline and a wide range of neurocognitive features associated with attention, memory, and response to motivational stimuli.\n\nSecondary Objectives:\n\n1. To document relations between baseline neurocognitive features and response to Cognitive Behavioral Therapy (CBT) or fluoxetine, as defined by the Pediatric Anxiety Rating Scale (PARS) and Clinical Global Improvement (CGI) Scale.\n2. To document relations between post-treatment changes in neurocognitive features and anxiety symptoms on the PARS following treatment with Cognitive Behavioral Therapy (CBT) or fluoxetine.\n3. To document relations among broad arrays of clinical, cognitive, and neural measures\n\nPrimary Endpoints:\n\nIndices of percent-signal change in hypothesized brain regions, comprising amygdala, striatum, and prefrontal cortex (PFC) for each fMRI and MEG paradigm.\n\nSecondary Endpoints:\n\n1. Treatment-response as defined by a continuous measure, the Pediatric Anxiety Rating Scale score (PARS), and a categorial measure, the Clinical Global Improvement (CGI) score.\n2. Levels of symptoms and behaviors evoked by tasks that engage attention, memory, and elicit responses to motivational stimuli.",[27,28],"Anxiety Disorders","Major Depressive Disorder",[30,31,32,33,34],"fMRI","Emotion","Normal Volunteers","Magnetic Resonance Imaging","CBT","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2001-10-02",{"date":43,"type":21},"2029-01-01",{"name":45,"class":46},"National Institute of Mental Health (NIMH)","NIH",2,{"id":49,"slug":50,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":25,"conditions":54,"keywords":55,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":61,"locationsCount":47},"100059514","phase-2-study-of-neuro-cognitive-correlates-of-pediatric-anxiety-disorders-100059514","* INCLUSION CRITERIA:\n\nALL JUVENILE SUBJECTS\n\n* Age: 8-17 (subjects who consent as 17-year-olds but turn 18 during the course of the study will be eligible to complete all procedures completed by other subjects who consent as 17-year-olds but do not turn 18).\n* Consent: can give consent\u002Fassent (Parents will provide consent; minors will provide assent)\n* IQ: all subjects will have IQ\\>70 (Assessment relies on either a WASI or assessment by trained clinical staff during the subject s screening visit. Completion of required activities during the screening visit requires an IQ above 70.)\n* Language: all subjects will speak English (Tasks in this protocol have not been validated in languages other than English)\n\nALL ADULT SUBJECTS\n\n* Age: 18-65\n* Consent: can give consent\n* IQ: all subjects will have IQ\\>70 (Assessment relies on either a WASI or assessment by trained clinical staff during the subject s screening visit. Completion of required activities during the screening visit requires an IQ above 70.)\n* Language: all subjects will speak English (Tasks in this protocol have not been validated in languages other than English)\n\nALL SUBJECTS WITH AN ANXIETY DISORDER\n\n* Diagnosis: Current Diagnosis of OCD, Social Phobia, Separation Anxiety, Generalized Anxiety Disorder, or Panic Disorder (Based on K-SADS (juveniles) or SCID (adults))\n* Symptom Severity: Clinically significant, ongoing anxiety symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n* Clinical Impairment: Clinically significant, ongoing distress or impairment from anxiety (This will be documented by clinician review with patients and their families during at least two visits with families.)\n\nALL PREVIOUSLY ENROLLED ADOLESCENT PATIENTS, CHILD AND ADULT HEALTHY VOLUNTEERS, AND ALL HEALTHY VOLUNTEERS TURNED PATIENTS\n\n* Diagnosis: Current Diagnosis of OCD, Social Phobia, Separation Anxiety, Generalized Anxiety Disorder, or Panic Disorder; No current diagnosis (Based on K-SADS (juveniles) or SCID (adults))\n* Clinical Impairment (as applicable): Clinically significant, ongoing symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n* Symptom Severity (as applicable): Clinically significant, ongoing symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n\nEXCLUSION CRITERIA:\n\nALL SUBJECTS\n\n* Any serious medical condition or condition that interferes with fMRI or M\u002FEEG scanning, and for patients electing medication, any condition that increases risk of SSRI treatment. (All patients will complete a medical history. Healthy volunteer participants will be medication- free and have no current serious medical conditions, based on a review of their medical history. Subjects only will be excluded from the MRI portions of the study based on this exclusion criterion.)\n* Pregnancy (Subjects only will be excluded from the MRI portions of the study based on this exclusion criterion.)\n* Current use of any psychoactive substance; current suicidal ideation; current diagnosis of attention deficit hyperactivity disorder (ADHD) of sufficient severity to require pharmacotherapy. (These factors could complicate treatment with an SSRI. No subject on medication will be accepted into the trial. Subjects will not be taken off of medications to enter the trial.)\n* Current diagnoses, major depressive disorder (MDD), post-traumatic distress disorder, conduct disorder. (These factors may be affected by SSRI treatment, influencing ability to detect effects on anxiety\u002Fsymptoms of depression. Of note, subjects who present with a diagnosis of MDD will not be eligible for inclusion at the outset of the study. However, youth with anxiety disorders frequently develop MDD when followed over time. Subjects will be allowed to remain in the study if they develop these diagnoses after enrollment.)\n* Past or current history of mania, psychosis, or severe pervasive developmental disorder. (These factors may be affected by SSRI treatment, influencing ability to detect effects on anxiety\u002Fsymptoms of depression. Of note, subjects who present with a diagnosis of MDD will not be eligible for inclusion at the outset of the study. However, youth with anxiety disorders frequently develop MDD when followed over time. Subjects will be allowed to remain in the study if they develop these diagnoses after enrollment.)\n* Recent use of an SSRI with failure to respond or tolerate SSRI treatment at an adequate dose and duration. (This is designed to exclude subjects who have failed a trial of an SSRI for their current problem with anxiety. For previously enrolled participants, including patients and healthy volunteers, current use of an SSRI does not exclude participation from follow-up research tasks.)\n* History of any (excepting nicotine-related and cannabis-related) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence).\n\nHEALTHY ADULT SUBJECTS\n\n-Any current psychiatric diagnosis (Assessment relies on SCID)",{"count":20,"type":21},[24],[27,28],[30,31,32,33,34],"2026-06-27",{"date":58,"type":39},"2026-06-30",{"date":41,"type":39},{"date":43,"type":21},{"name":45,"class":46},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":15,"sex":16,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":4,"leadSponsor":91,"locationsCount":92},"100059955","evaluation-of-patients-with-mood-and-anxiety-disorders-and-healthy-volunteers-100059955","NCT00024635","Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers","The Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers","* INCLUSION CRITERIA:\n* Subjects ages 3 to 99 may enroll in the protocol.\n* Subjects must be competent to comprehend the purpose of the screening process and to provide written informed consent and be willing to participate in NIMH IRB approved research protocols. Minors will be asked to assent and their parents will sign the consent form.\n\nEXCLUSION CRITERIA:\n\n-Current alcohol or substance use or dependence (excluding nicotine) within the past 3 months of sufficient magnitude to require independent, concurrent treatment intervention (e.g. Antabuse or opiate treatment, but not including self-help groups).","3 Years","99 Years",{"count":72,"type":21},16000,"OBSERVATIONAL","The purpose of this protocol is to allow for the careful screening of patients and healthy volunteers for participation in research protocols in the Experimental Therapeutics and Pathophysiology Lab (ETPB) at the National Institute of Mental Health (NIMH) and for the collection of natural history data. In addition the protocol will allow clinicians to gain more experience in the use of a variety of polysomnographic and high-density EEG recordings. Subjects in this protocol will undergo an evaluation which may include: a psychiatric interview; a diagnostic interview; rating scales; a medical history; a physical exam; brain magnetic resonance imaging (MRI); electroencephalography (EEG); electrocardiography (EKG), magnetoencephalography (MEG); blood, saliva and urine laboratory evaluation; and a request for medical records. Subjects may also be asked to complete questionnaires about attitudes towards research and motivation for research participation. The data collected may also be linked with data from other mood and anxiety disorder protocols (e.g., brain imaging, DNA, psychophysiology tests, treatment studies, etc) for the purposes of better understanding the diagnosis, pathophysiology, and treatment response of patients with mood disorders. Parents of minors will be interviewed. Upon conclusion of the screening process, subjects will either be offered participation in a research protocol and will sign the appropriate informed consent, or will be considered not appropriate for participation in research and will be referred back into the community. The current protocol thus serves as an entry point for individuals with mood or anxiety disorders or healthy volunteers to enter NIMH IRB approved ETPB protocols.",[76,27,77,78,79],"Mood Disorders","Healthy Volunteers","Bipolar Disorder","Depression",[81,82,83,84,85],"Screening","Anxiety","Mood","Diagnostic Testing","Natural History","2026-06-24",{"date":88,"type":39},"2026-06-25",{"date":90,"type":39},"2001-02-02",{"name":45,"class":46},1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":92},"100561883","phase-2-gaze-contingent-music-therapy-augmentation-of-cbt-for-pediatric-anxiety-100561883","NCT06595953","Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety","Phase II Efficacy Study of Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Ability of subject and parent to understand the study and the willingness to assent\u002Fconsent into the study.\n2. Males and females; Age 8-17\n3. Clinician confirmed diagnosis of ongoing separation anxiety disorder, generalized anxiety disorder, or social anxiety disorder. A clinician will review a KSADS-PL DSM-5 (November 2016) (Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children) interview, which will have occurred on Protocol 01-M-0192, to confirm diagnosis\n4. Willingness to adhere to 12 weekly in-person sessions of CBT\n5. Enrolled in Protocol 01-M-0192\n6. Subjects must speak, read and write English to be able to participate\n7. All subjects will have IQ\\>70 as assessed by a WASI or assessment by trained clinical staff which will have occurred under Protocol 01-M-0192\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current use of any psychotropic medication\n2. Ongoing participation in another treatment or intervention study\n3. Ongoing mental health treatment outside of NIH\n4. Any mental health diagnosis aside from an anxiety disorder as determined by the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)\n5. Any serious medical conditions\n6. Restrictions that preclude in-person attendance of therapy","17 Years",{"count":102,"type":21},150,[24],"Background:\n\nAnxiety disorders are becoming more common among children and teenagers. Anxiety can lead to long-term physical and mental problems, such as depression. Treatments for anxiety disorders include medications as well as cognitive behavioral therapy (CBT); CBT is a form of talking therapy. Both approaches work in only about 50 percent of cases. A new approach, called gaze-contingent music reward therapy (GCMRT), may help.\n\nObjective:\n\nTo find out whether GCMRT combined with CBT is more effective than CBT alone.\n\nEligibility:\n\nChildren aged 8 to 17 years with separation anxiety disorder; generalized anxiety disorder; or social anxiety disorder. They must be enrolled in protocol 01-M-0192.\n\nDesign:\n\nParticipants will come to the clinic once a week for 4 weeks for CBT. Sometimes the participant will meet with the doctor alone; sometimes their parent may be present. They will do some computer-based tasks: They may be asked to push a button when a target appears; they may look at pictures of faces while the computer tracks their eye movements. Participants will take questionnaires each week. They will answer questions about their anxiety symptoms, feelings, and behavior.\n\nFor the next 8 weeks, participants will participate in both CBT and 1 of 2 types of GCMRT.\n\nGCMRT is a computer-based task. Participants will look at pictures with many faces in them; while they do this, pleasant music will play and stop playing over a 12-minute period.\n\nParticipants will have a final visit in week 13. They will take questionnaires. They will do final research tasks. Each visit lasts about 2 hours.",[106,27],"Psychiatric Disorders",[108,109,82,110,111],"Cognitive-behavioral therapy","Attention","Children","Adolescents","2026-06-23",{"date":86,"type":39},{"date":115,"type":39},"2024-12-04",{"date":117,"type":21},"2029-10-01",{"name":45,"class":46},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":152},"100644110","digital-coach-to-support-exposure-therapy-homework-for-anxious-youth-100644110","NCT07666672","Digital Coach to Support Exposure Therapy Homework for Anxious Youth","Randomized Controlled Trial of the BraveBot Intervention as an Adjunctive Treatment for Young People With Anxiety and Related Disorders Receiving Outpatient, Exposure-Based Cognitive Behavioral Therapy","INCLUSION CRITERIA (youth participants):\n\n1. Has a clinical or subclinical anxiety or related disorder (e.g., panic disorder, social anxiety disorder, obsessive-compulsive disorder) for which exposure-based CBT is indicated.\n2. Between the ages of 12 and 22 years at the time of enrollment.\n3. Is either (a) currently receiving exposure-based CBT (or CBT in which exposure-based content is expected to be a core component) at a participating MGB outpatient program, or (b) on the waitlist for a participating program and expected to initiate exposure-based CBT in the near future.\n4. Sufficient ability to communicate in English (study materials, measures, and the BraveBot interface are currently English-only). For minors, at least one parent\u002Fguardian must be sufficiently proficient in English to understand the consent information.\n5. The youth and\u002For caregiver has access to a device that can receive SMS text reminders and open secure web links to complete exposure homework and brief post-exposure surveys.\n\nEXCLUSION CRITERIA (present at enrollment):\n\n1. Symptoms of suicidal or homicidal ideation, psychosis, or a non-anxiety-related primary mental health concern (i.e., where treatment for a disorder other than anxiety is indicated prior to exposure treatment, or independent exposure homework is not clinically appropriate as determined by the treating clinician). Examples include: current substance use or dependence requiring specialized or higher-level care that must be addressed before or instead of anxiety-focused exposure-based CBT; and current eating disorder severe enough to require intensive\u002Fspecialized treatment such that exposure-based CBT for anxiety\u002FOCD is not the appropriate primary focus.\n2. Youth is unable to complete homework independently.\n3. Any other condition or circumstance for which treatment for another primary psychiatric condition is clearly indicated prior to anxiety-focused exposure-based CBT, or for which out-of-session exposure homework is considered unsafe or inappropriate.\n\nThe investigators will also recruit up to 10 clinicians at participating programs who may use the BraveBot system with their patients (who have enrolled in the study independently) and complete brief baseline and end-of-study surveys.","12 Years","22 Years",{"count":129,"type":21},50,[131],"NA","This study is testing a digital tool called BraveBot for young people who are receiving cognitive behavioral therapy (CBT) for anxiety, OCD, or related problems. BraveBot is a computer program, not a person. It talks with youth through their phone or computer while they do \"face-your-fears\"-style exposure therapy homework that their therapist has assigned. Sometimes an exposure is done with BraveBot's real-time coaching, and sometimes on their own; after each exposure, youth answer a few short questions about how it went.\n\nRather than dividing participants into separate groups, the study randomizes each individual exposure homework assignment. Every time a young person opens an eligible exposure, the system makes a 1:1 random assignment deciding whether that exposure is completed with BraveBot's support or independently (self-guided).\n\nThe main goal is to learn whether using BraveBot helps youth understand their exposure assignments better, put in more effort, stick with exposures when they are hard, feel more capable, and find exposures more helpful in \"fighting back\" against anxiety. The study also examines whether BraveBot increases the likelihood that assigned exposures are completed, and explores effects on anxiety symptoms and how safe, easy to use, and useful BraveBot feels for youth, their therapists, and parents.\n\nBraveBot does not replace the therapist, diagnose, or design exposures; it only supports the homework the clinician has assigned, and is used under clinician oversight. A built-in safety system can detect possible risk-related language, pause the session, show crisis resources (such as 988), and notify the treating clinician. The study is conducted within routine outpatient psychology clinics at Mass General Brigham. Up to 40 youth ages 12-22 will take part.",[27,134],"OCD",[136,137,138,139,140,141],"anxiety","exposure therapy","pediatric","large language model","conversational AI","randomized controlled trial","NOT_YET_RECRUITING","2026-06-18",{"date":86,"type":39},{"date":146,"type":21},"2026-07-15",{"date":148,"type":21},"2027-07-15",{"name":150,"class":151},"Massachusetts General Hospital","OTHER",3,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":15,"sex":16,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":92},"100527171","whole-body-hyperthermia-for-mood-and-anxiety-disorders-100527171","NCT06144294","Whole-Body Hyperthermia for Mood and Anxiety Disorders","Inclusion Criteria\n\n* Group 2\n\n  * Arm 1: Healthy women or transgender men 18-50 years of age, ≤ 6 months postpartum\n  * Arm 2: Women and transgender men 18-50 years of age, ≤ 6 months postpartum, meeting criteria for a major depressive episode in the postpartum period on the MINI.\n  * Arm 3: Healthy adults of both sexes 18-50 years of age.\n  * Arm 4: Adults of both sexes 18-50 years of age meeting criteria for an episode of major depression or generalized anxiety disorder on the Mini International Neuropsychiatric Interview (MINI)\n* Group 2: Sub-study\n\n  * Subjects enrolled in Group 2 are eligible for an optional additional sub-study (Group 2: Sub-study); inclusion criteria are the same as for Group 2.\n\nExclusion criteria for all:\n\n* For logistics, we will exclude individuals with BMI \\>30 and waist size \\> 35, who may not fit comfortably in the sauna dome for all cohorts described above.\n* For contraindications to hyperthermia, we will exclude from all cohorts listed above, individuals with severe cardiovascular disease, including congestive heart failure, coronary artery disease, uncontrolled hypertension, and hypotension; pregnancy; active substance use disorders; recent major injuries or surgeries (\\\u003C1 week prior); impaired sweating (those with multiple sclerosis, diabetes mellitus with neuropathy, central nervous system disease, heat insensitivity); a history or family history of malignant hyperthermia, fever or active signs of infection; taking medications that may have interactions with hyperthermia (for example, barbiturates, diuretics, and beta blockers) and the use of an antipyretic or anihistamine medication in the 12 hours prior to the WBH intervention. Individuals with above mentioned conditions will be excluded since either WBH might deteriorate their conditions or it is unknown how their condition will be affected by WBH.\n* For contraindications to immune analyses, we will exclude individuals with conditions that might affect immune analyses, including individuals with known active autoimmune or endocrine disease and individuals with active infection at baseline.\n\nAdditional exclusion criteria by cohort or applicable study group:\n\n* Group 2\n\n  * Arm 1: For psychiatric contraindications, we will exclude individuals with a history of psychiatric disorders as assessed by MINI since the cohort will consist of mentally healthy individuals as a control group.\n  * Arm 2: For psychiatric contraindications, we will exclude individuals with bipolar disorder or other Axis I psychiatric disorders except depressive and anxiety disorders and individuals taking antidepressants who are unwilling to hold antidepressant dose steady from recruitment through study termination. In this cohort we exclude individuals with other psychiatric disorders except depressive and anxiety disorders to rule out the effect of other psychiatric diseases on the outcome.\n  * Arm 3: For psychiatric contraindications, we will exclude individuals with a history of psychiatric disorders as assessed by MINI since the cohort will consist of mentally healthy individuals as a control group.\n  * Arm 4: For psychiatric contraindications, we will exclude individuals with bipolar disorder or other Axis I psychiatric disorders except depressive and anxiety disorders and individuals taking antidepressants who are unwilling to hold antidepressant dose steady from recruitment through study termination. In this cohort we exclude individuals with other psychiatric disorders except depressive and anxiety disorders to rule out the effect of other psychiatric diseases on the outcome.\n* Group 2 and Group 2: Sub-study - All participants\n\n  * For contraindications to use of the e-Celsius capsule that will be used to measure core temperature, we will exclude individuals with pacemakers or any other electric medical implant, individuals with a current intestinal disorder that could lead to obstruction of the digestive tract including gastroparesis, individuals with history of diverticula, individuals with history of past surgical procedures in the gastrointestinal tract, individuals with a swallowing disorder and individuals with Crohn's disease.\n* Study Group 3 - All participants\n\n  * For contraindications to MRI, individuals with metal in the body will be excluded from participating in the MRI portion of the research since magnetic fields in MRI scanners can cause dangerous interactions in patients with metallic foreign bodies: projectile effect, twisting, burning, artifacts, and device malfunction (interference with a pacemaker).","18 Years","50 Years",{"count":162,"type":21},240,[131],"This study aims to examine the scientific mechanisms of whole-body hyperthermia (WBH), a novel, rapidly acting, single session antidepressant and anxiolytic therapy. It also aims to determine its feasibility and acceptability in women with postpartum depression (PPD). The study will enroll four cohorts of participants: healthy postpartum controls; postpartum women with PPD; healthy adult controls; and adults with major depressive disorder or anxiety disorders in a longitudinal protocol.",[166,76,27,167],"Postpartum Depression","Postpartum Anxiety",[169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,30],"postpartum depression","mood disorders","anxiety disorders","postpartum anxiety","whole-body hyperthermia","antidepressant therapy","anxiolytic therapy","postpartum feasibility and acceptability","psychoneuroimmunology","Broad-band neural suppression","EEG","Likert scale","inflammatory activity","pro-inflammatory cytokines","precision functional brain maps",{"date":112,"type":39},{"date":186,"type":21},"2028-06",{"date":188,"type":21},"2032-12",{"name":190,"class":151},"Weill Medical College of Cornell University",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":126,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":92},"100642990","feasibility-study-of-up-a-ast-parent-group-for-adolescents-with-autism-and-co-occurring-anxietydepression-100642990","NCT07637799","Feasibility Study of UP-A-AST Parent Group for Adolescents With Autism and Co-occurring Anxiety\u002FDepression","Unified Protocol-Adolescent Autism Parent Group (UP-A-AST) for Adolescents With Autism Spectrum Disorder and Co-occurring Anxiety and\u002For Depressive Disorders: A Feasibility Study","Inclusion Criteria:\n\n* Adolescents aged 12-17 years\n* Clinical diagnosis of autism spectrum disorder (ASD) according to DSM-IV, DSM-5, or ICD-10\n* Current diagnosis of anxiety disorder and\u002For depressive disorder according to DSM-5\n* Ongoing contact with a Child and Adolescent Psychiatry (BUP) outpatient clinic\n* Stable psychopharmacological treatment at the time of inclusion (if applicable)\n* Parents has participated in a psychoeducational program on autism within child and adolescent psychiatric services, or is assessed by the clinician to have equivalent knowledge\n\nExclusion Criteria:\n\n* Presence of a severe psychiatric disorder, such as psychotic disorder, bipolar disorder, or severe eating disorder\n* High suicide risk or suicide attempt within the past 12 months\n* Severe self-injurious behavior\n* Intellectual disability according to DSM-5\n* The adolescent is primarily in need of basic interventions for autism spectrum disorder\n* Parents are unable to attend all group sessions and\u002For lack the ability to engage in assigned home practice\n* Need for an interpreter",{"count":199,"type":21},72,[131],"Autism spectrum disorder (ASD) is associated with high rates of psychiatric comorbidity, particularly anxiety and depressive disorders, which contribute to significant impairment for affected youth and their families. Although cognitive behavioral therapy (CBT) is recommended as a first-line treatment for anxiety and depression in children and adolescents, there is a lack of evidence-based interventions specifically adapted for youth with ASD and co-occurring emotional disorders.\n\nThe Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C\u002FUP-A) is a CBT-based intervention targeting shared mechanisms underlying anxiety and depression. A parent-mediated adaptation, the Unified Protocol-Adolescent Autism Parent Group (UP-A-AST), has been developed to address the specific needs of adolescents with ASD and co-occurring anxiety and\u002For depressive disorders. Preliminary quality improvement work has shown promising results.\n\nThis study aims to evaluate the feasibility, acceptability, and preliminary effects of the UP-A-AST Parent Group in a child and adolescent outpatient psychiatric setting. The study will include parents of adolescents aged 12-17 years with ASD and co-occurring anxiety and\u002For depressive disorders. Outcomes include changes in adolescents' psychiatric symptoms and functional impairment, as well as parents' perceived parenting competence. Additionally, parents' experiences of participating in the intervention will be explored.",[203,27,204],"Autistic Spectrum Disorder","Depressive Disorder","2026-06-09",{"date":207,"type":39},"2026-06-10",{"date":209,"type":39},"2026-01-05",{"date":211,"type":21},"2027-03-30",{"name":213,"class":151},"Sahlgrenska University Hospital",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":92},"100513239","development-of-a-transdiagnostic-intervention-for-adolescents-at-risk-for-serious-mental-illness-100513239","NCT05962879","Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness","Inclusion Criteria:\n\n* Currently enrolled in 9th through 12th grade and between the ages of 14 and 19\n* Endorsed at least one psychotic experience\n* Provided contact information\n* Have a parent or legal guardian who is able and willing to provide written informed consent (if under the age of 18)\n* Have a parent or legal guardian who is able and willing to participate in a parent session\n* Competent and willing to provide written informed assent (if under the age of 18) or consent (if age 18 or older)\n* Able to communicate in English\n\nExclusion Criteria:\n\n* Currently prescribed psychotropic medication (not including medications for attention deficit\u002Fhyperactivity disorder), regardless of adherence\n* Currently obtaining psychotherapeutic intervention","14 Years","19 Years",{"count":223,"type":21},70,[131],"This research study aims to develop a brief group-based treatment called Resilience Training for Teens, then to test how well it protects high school students with mild symptoms of depression, anxiety, or having unusual feelings from developing mental illnesses.",[27,227,204,228],"Psychotic Disorders","Psychosocial Functioning",{"date":230,"type":39},"2026-06-11",{"date":232,"type":39},"2024-03-22",{"date":234,"type":21},"2027-05-31",{"name":150,"class":151},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":242,"maxAge":159,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":253,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":92},"100642279","experimental-evidence-of-the-impact-of-parental-income-on-child-mental-health-and-neuroimmune-function-100642279","NCT07641244","Experimental Evidence of the Impact of Parental Income on Child Mental Health and Neuroimmune Function","Inclusion Criteria:\n\n* Child of a participant enrolled in the Every Dollar Counts intervention. Youth were between ages 5 and 14 at the start of the intervention (followed up when ages 10 to 18)\n* Biological parent who lives with the child must be part of the original income study\n* For the in-person neuroimaging subsample: family must live within a 2-hour drive of downtown Chicago\n\nExclusion Criteria:\n\n* Youth not between ages 5 and 14 at the start of the intervention\n* Parent not enrolled in the Every Dollar Counts program","10 Years",{"count":244,"type":21},500,[131],"Growing up in a lower-income family robustly predicts worse mental health in adolescence and early adulthood. How does variability in family income \"get under the skin\" of the developing child and via what mechanisms does it increase risk for mental illness? Moreover, could supplements to family income at critical developmental periods help to prevent later youth mental illness? To address these questions, we leverage an innovative existing double blind randomized controlled trial of 3-years of substantial income supplements to parents.\n\nBy experimentally studying the impacts of these income supplements on families and subsequent youth development, we can examine causal pathways from family income to risk for mental illness via family stress and neuroimmune mechanisms in ways never done before. Moreover, by measuring the longer-term impact of 3 years of income supplements to parents on their child's neuroimmune signaling and risk for mental illness, we can examine the policy implications for child development of unconditional cash transfers to parents and identify how and for whom these supplements help. We will test these basic and translational questions in a sample of 1,200 youth with lower-income parents randomly assigned to receive either a substantial monthly income supplement or a minimal monthly supplement for 3 years, starting when youth were between age 5 - 14 years old. We will follow up with youth and their parent 1 - 2 and 3 - 4 years after the intervention and examine whether income supplements predict better youth mental health during adolescence, as well as whether factors like child age and neighborhood quality modulate intervention effects. Additionally, we explore family stress mechanisms through which the intervention may impact child mental health. Finally, we will measure peripheral inflammation (inflammatory biomarkers and classical monocytes) and use MRI to assess threat, reward, and regulatory neural activity and connectivity among 500 of these youth. Our central hypothesis is that income supplements will decrease family and youth stress and improve parenting, which will improve neuroimmune signaling and decrease risk for psychopathology. Moreover, these effects will remain years after termination of the transfers and be strongest among families who received the intervention earlier in the child's life. This research will provide timely, relevant public health knowledge that will help policy makers understand the longer-term brain, immune, and mental health impacts of cash transfers to parents, while also advancing the science of the sociocontextual and neuroimmune pathways through which variability in family income impacts risk for psychopathology.",[248,249,27,250,251,252],"Psychopathology","Child Mental Health","Mental Disorders","Inflamation","Poverty",[79,82,254,255,256,252,249,248,257],"Internalizing Disorders","Externalizing Disorders","Inflammation","Stress","2026-06-08",{"date":230,"type":39},{"date":261,"type":39},"2026-04-04",{"date":263,"type":21},"2029-08-31",{"name":265,"class":151},"Northwestern University",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":15,"sex":16,"minAge":274,"maxAge":159,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":92},"100642699","study-on-mental-health-promoting-effects-of-natural-psychotherapy-for-adolescents-100642699","NCT07639476","Study on Mental Health Promoting Effects of Natural Psychotherapy for Adolescents","The Effect of Universal Intervention Based on Natural Psychotherapy: Evidence From Chinese Adolescents","NP-A-MHP","Inclusion Criteria:\n\n* Ages: 7 to 18 years.\n* Population: School-aged children and adolescents currently enrolled and attending primary or secondary school.\n* Capacity: Ability to comprehend the study procedures and provide assent (or consent, if applicable).\n\nExclusion Criteria:\n\n* School Attendance: Children not currently attending school or on long-term academic leave.\n* General Exclusion: Any condition that, in the opinion of the investigator or school physician, would interfere with the participant's ability to attend school or comply with study procedures.","7 Years",{"count":276,"type":21},3000,[131],"This randomized controlled trial aims to evaluate the efficacy of a universal intervention based on Natural Psychotherapy in reducing anxiety and depressive symptoms among primary and middle school students. To evaluate both the clinical outcomes and the potential underlying mechanisms of change, data will be collected at four distinct time points: baseline (pre-intervention), post-intervention, 3-month follow-up, and 6-month follow-up.",[27,204,280],"Mental Health",[282,79,283,284,285,286,287,288],"Mindfulness","Emotional Regulation","Cognitive Flexibility","Primary School Students","Middle School Students","Feasibility","Natural Psychotherapy","2026-06-06",{"date":207,"type":39},{"date":292,"type":21},"2026-09-15",{"date":294,"type":21},"2027-12-31",{"name":296,"class":151},"Beijing HuiLongGuan Hospital",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":15,"sex":16,"minAge":159,"maxAge":18,"enrollmentInfo":304,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":4,"leadSponsor":319,"locationsCount":92},"100087463","development-of-magnetic-resonance-imaging-techniques-for-studying-mood-and-anxiety-disorders-100087463","NCT00397111","Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders","Development of Functional and Structural Magnetic Resonance Imaging Techniques for the Study of Mood and Anxiety Disorders","* INCLUSION CRITERIA:\n\nHealthy Controls\n\n* Male and female subjects between 18 and 65 years of age\n* Subjects must be able to give written informed consent prior to participation in this study.\n* Subjects who do not currently meet and have never met criteria for any major psychiatric disorder, and who have no known first degree relatives with mood disorders.\n* For cognitive experiments utilizing language stimuli only native English speakers will be enrolled.\n\nMajor Depressive Disorder\n\n* Male and female subjects between 18 and 65 years of age.\n* Subjects have been found eligible for other ETPB research protocols according to 01-M-0254.\n* Subjects must fulfill DSM-IV or V criteria for Major Depression based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P).\n* Subjects must be able to give written informed consent prior to participation in this study.\n* For cognitive experiments utilizing language stimuli, only native English speakers will be enrolled.\n\nEXCLUSION CRITERIA:\n\nHealthy Control\n\n* Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology, or taking any medication that is likely to influence the imaging parameters-of-interest within 3 weeks of scanning.\n* Women who are pregnant are excluded from the study. Subjects will undergo pregnancy testing no more than 24 hours prior to MRI scanning.\n* Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.\n* A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).\n\nMajor Depressive Disorder\n\n* Presence of Axis 1 psychiatric diagnosis other than Major Depression or an Axis 2 disorder\n* Subjects with major medical or neurological disorders expected to influence cognitive function or are taking any drugs likely to affect mood or cognitive function within 1 week of study participation. Depressed subjects will not be tapered\u002Fwithdrawn from medications under this study.\n* A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).\n* Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology.\n* Women who are pregnant or breastfeeding will be excluded from MRI portions of the study. Subjects will undergo pregnancy testing no more than 24 hours prior to MRI scanning.\n* Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.",{"count":305,"type":21},390,"This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers believe that depression and anxiety disorders may cause structural and functional changes in the brain. This study will optimize the way MRI scans are collected to look at brain structure and examine how the brain behaves while subjects perform particular tasks. Healthy volunteers and individuals with major depressive disorder may be eligible for this study.\n\nParticipants undergo magnetic resonance imaging (MRI) and neuropsychological testing. : Individuals will be asked to participate in an MRI study on one of several scanners. The scanner used will measure blood flow in the brain, concentrations of certain chemicals in the brain, or magnetic properties of the brain. The scan may involve They watching a screen presenting images or doing a task in which they respond to pictures or sounds. Participants may be asked to return for additional scans.\n\nThe study also involves neuropsychological tests, which assess cognitive performance. Often, people with mood disorders have subtle changes in performance on these tests that allow researchers to pinpoint where brain abnormalities occur. Before the tests can be used in patients, they must be validated by using healthy subjects. These tests are presented either orally, in written form, or on a computer.",[76,27],[309,310,30,311,312,85,313,314],"Morphometry","BOLD","Spectrometry","Relaxometry","Healthy Volunteer","HV","2026-06-05",{"date":258,"type":39},{"date":318,"type":39},"2006-12-06",{"name":45,"class":46},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":152},"100489874","rxwell-to-decrease-post-operative-opioid-use-in-total-knee-or-hip-arthroplasty-100489874","NCT05658796","RXWell to Decrease Post-Operative Opioid Use in Total Knee or Hip Arthroplasty","Telemedicine-delivered Digital Cognitive Behavioral Intervention to Decrease Post-operative Opioid Use Among Patients Undergoing Total Knee or Hip Arthroplasty","RxWell","Inclusion Criteria for the RXWell Study:\n\n* Adults \\>18 years\n* Scheduled for elective primary total knee arthroplasty (TKA) or hip replacement (THA) at the approved UPMC hospitals\n* Moderately high levels of mood disorder symptoms on validated PROMIS measures, defined as a T-score \\> or = to 60 on PROMIS Anxiety 4a short form and\u002For PROMIS Depression4a short form\n\nExclusion Criteria for the RXWell Study:\n\n* Patients undergoing non-elective surgery or secondary arthroplasty\n* Active delirium, neurocognitive impairment, or severe intellectual disability\n* No access to a smart device (phone or tablet)\n* Active alcoholism (defined as daily use of more than 1 liter of wine and \u002For 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)\n* Profound mood disorders requiring immediate intervention such as suicidal ideation, defined as a PROMIS Depression score of more than 70\n* A PROMIS Anxiety and\u002For Depression T-score \\>70, which corresponds to severe anxiety and depression.\n\n  * Patients needing immediate care will be referred to psychiatrists and primary team.","100 Years",{"count":102,"type":21},[131],"It is envisioned that multipronged benefits from this pilot work for the UPMC ISD and its members. It is expected the RxWell platform to provide the following benefits: expansion of the use of RxWell to all UPMC ISD members providing peri-operative mood management with advantage of improved peri-operative outcomes, improving saving for the UPMC ISD by hastening the recovery and decreased resource utilization, and addition to the high-value care of UPMC with this holistic approach to patient perioperative care",[76,82,333,79,27,334],"Depressive Symptoms","Anxiety Depression","2026-06-01",{"date":337,"type":39},"2026-06-03",{"date":339,"type":39},"2023-01-27",{"date":341,"type":21},"2026-12-30",{"name":343,"class":151},"University of Pittsburgh",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":370},"100489695","clinical-study-evaluating-pharmacogenomics-informed-pharmacotherapy-versus-dosing-as-usual-in-psychiatric-disorders-100489695","NCT05656469","Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders","A New Intervention for Implementation of Pharmacogenetics in Psychiatry","PSY-PGx","Inclusion Criteria:\n\n1. Suffer from a depressive episode (major depressive disorder and bipolar disorder (currently depressive episode)) (as assessed by the MINI International Neuropsychiatric Interview (M.I.N.I.) in agreement with Diagnostic and Statistical Manual (DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Depression Scale (SIGH-D) with a score of 14 or higher) and\u002For suffer from an anxiety disorder (panic disorder, generalised anxiety disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH- A) with a score of 18 or higher) and\u002For suffer from a psychotic disorder (schizophrenia and schizoaffective disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Positive and Negative Symptom Scale (PANSS) with a score of 75 or higher).\n2. Have had an inadequate response to at least 1 psychotropic treatment during their life-time. Inadequate response is defined as insufficient efficacy of a psychotropic treatment when dosed high enough and maintained long enough, or discontinuation of a psychotropic treatment due to AEs or intolerability.\n3. Are about to switch (or have switched within the last 2 weeks prior to first contact with an investigator) to sertraline or escitalopram (for patients with mood or anxiety disorders), or to aripiprazole or risperidone (for patients with psychotic disorders) due to an inadequate response to or intolerance of the current\u002F previous medication.\n4. Currently receiving inpatient or outpatient psychiatric treatment.\n5. Be able to understand the requirements of the study and provide written informed consent to participate in this study; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.\n6. To give written consent to the use and disclosure of clinical data from their medical records for the purpose of this study.\n7. Age between ≥16 and \\\u003C70 years.\n8. Ownership of a mobile phone (Android or iOS operation system) for passive monitoring.\n\nExclusion Criteria:\n\n1. Patients with a history of prior pharmacogenomic testing\n2. Patients with no prior use of psychotropic medication (medication-naïve patients)\n3. Severe somatic comorbidities as reported in the subject's medical history or based on clinical chemistry\u002Felectrocardiography (ECG) results up to six months ago. If any of these comorbidities is detected on the basis of physical examination and\u002For clinical chemistry and\u002For ECG at the screening visit, participation is not possible.\n\n   * Liver disease defined as follows: Alanine-Aminotransferase (ALAT) \\>70u\u002FL\n   * Renal disease: Estimated glomerular filtration rate (eGFR) \\\u003C 60ml\u002Fmin\u002F1.73m2\n   * Diabetes: Blood glucose \\> 11.1 mmol\u002FL or twice a fasting glucose \\> 7.0 mmol\u002FL\n   * Cardiac disease: prolonged QT-interval.\n4. Alcohol and\u002For substance abuse and\u002For dependence (except nicotine)\n5. Polypharmacy defined as the routine use of five or more medications including over- the-counter, prescription and\u002For traditional and complementary medicines used by a patient (WHO 2019).\n6. Inability to use the mobile phone application\n7. Pregnant or breastfeeding women","16 Years","70 Years",{"count":355,"type":21},2500,[131],"A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.",[76,27,227],[360],"Pharmacogenetics","2026-05-29",{"date":363,"type":39},"2026-06-02",{"date":365,"type":39},"2023-02-23",{"date":367,"type":21},"2026-09",{"name":369,"class":151},"Parnassia Groep",9,{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":378,"minAge":159,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":152},"100590485","right-prefrontal-autonomic-mapping-in-recurrent-pregnancy-loss-with-comorbid-anxiety-100590485","NCT06968026","Right Prefrontal Autonomic Mapping in Recurrent Pregnancy Loss With Comorbid Anxiety","Acute Cardiac Autonomic Responses to High-intensity, Low-frequency, Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex in Women With Recurrent Pregnancy Loss and Comorbid Anxiety Disorders: a Proof-of-concept rTMS-ECG Parameter-finding Trial (NEURO-CARD-rTMS-1)","* Inclusion Criteria:\n\n  * 1)Female, aged 18-45 years, and right-handed.\n  * 2)Diagnosis of recurrent pregnancy loss (RPL), defined as ≥2 consecutive spontaneous miscarriages before 28 weeks of gestation.\n  * 3)Currently non-pregnant, or presenting with a missed abortion (no fetal cardiac activity confirmed by ultrasound).\n  * 4)Hamilton Anxiety Rating Scale (HAMA) score ≥14 and Hamilton Depression Rating Scale (HAMD-17) score ≤17 (to exclude clinically significant depression).\n  * 5)Diagnosis of generalized anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The diagnosis will be established through a structured diagnostic interview conducted by a qualified attending-level or senior psychiatrist, either on site or, when on-site assessment cannot be completed, through a secure encrypted video-conferencing platform with multidisciplinary team support.\n* Exclusion Criteria:\n\n  * 1\\) Contraindications to transcranial magnetic stimulation (TMS), including metallic implants or a history of epilepsy;\n  * 2\\) Uncontrolled blood pressure (systolic \\>180 mmHg or \\\u003C90 mmHg);\n  * 3\\) Presence of other major medical conditions, including hyperthyroidism, a history of atrial fibrillation, valvular heart disease, sinus bradycardia, neurological disorders, cerebrovascular disease, or chronic pulmonary disease;\n  * 4)Current use of psychotropic medications at the time of screening, to avoid hemodynamic or autonomic confounding;\n  * 5\\) Clinically significant suicide risk;\n  * 6\\) A current or past diagnosis of other psychiatric disorders, including substance use disorders, schizophrenia, delusional disorder, unspecified psychotic disorder, bipolar disorder, or delirium.","FEMALE","45 Years",{"count":381,"type":21},55,[131],"Recurrent pregnancy loss is often accompanied by substantial anxiety and may also be associated with autonomic imbalance and increased long-term cardiovascular vulnerability. The present proof-of-concept rTMS-ECG parameter-finding trial will examine whether high-intensity, low-frequency, periodic repetitive transcranial magnetic stimulation (rTMS) delivered over the right dorsolateral prefrontal cortex can induce detectable acute cardiac autonomic responses in women with recurrent pregnancy loss and comorbid anxiety disorders.\n\nA total of 55 women will be enrolled. During a single experimental session, each participant will undergo a stimulation-intensity sweep protocol with six consecutive stimulation cycles at 100%, 110%, 120%, 130%, 140%, and 150% of resting motor threshold. Each cycle will consist of 40 seconds of 1 Hz stimulation followed by a 20-second rest interval, while electrocardiography will be recorded continuously throughout the procedure. The study will evaluate baseline-corrected heart-rate change, wavelet-derived power near the stimulation-cycle frequency, and the rTMS-induced cardiac coupling index across intensity conditions. The goal is to identify the candidate stimulation intensity that produces the most detectable and physiologically consistent acute cardiac autonomic response for transfer to subsequent NEURO-CARD-rTMS studies.",[385,27],"Recurrent Pregnancy Loss",[387,171,388,389,390],"Recurrent pregnancy loss","repetitive transcranial magnetic stimulation","dorsolateral prefrontal cortex","autonomic modulation","2026-05-22",{"date":393,"type":39},"2026-05-26",{"date":395,"type":39},"2025-05-16",{"date":397,"type":21},"2026-05-13",{"name":399,"class":400},"Shenyang Jinghua Hospital","INDUSTRY",{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":409,"maxAge":100,"enrollmentInfo":410,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":425,"locationsCount":92},"100358895","pharmacogenetics-of-antidepressant-induced-disinhibition-100358895","NCT03953014","Pharmacogenetics of Antidepressant-Induced Disinhibition","Pharmacogenetics of Antidepressant-Induced Disinhibition in Children Study","PGx-AID","Inclusion Criteria:\n\n1. Aged 6 - 24 years\n2. Medical records available\n3. Diagnosis of MDD, anxiety disorder, or OCD\n4. Current or past history of SSRI therapy\n\nExclusion Criteria:\n\n1. Inability of parent\u002Flegal guardian to give informed consent\n2. Inability of the child to give informed assent\n3. Unwillingness of child to provide saliva sample for genetic analysis\n4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.","6 Years",{"count":411,"type":21},120,"The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and\u002For obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[414,27,28,415],"Obsessive-Compulsive Disorder","Antidepressant Drug Adverse Reaction",[417,79,110,134,82,418],"SSRI","Antidepressants","2026-05-11",{"date":421,"type":39},"2026-05-14",{"date":423,"type":39},"2019-01-02",{"date":341,"type":21},{"name":426,"class":151},"University of Calgary",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":92},"100587519","a-preventive-behavioral-intervention-for-young-adults-with-psychotic-experiences-100587519","NCT06929442","A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences","A Randomized Controlled Trial of a Preventive Behavioral Intervention for Young Adults With Psychotic Experiences","Inclusion criteria:\n\n1. 18-30 years old\n2. Enrolled as a first or second year student (i.e., freshman or sophomore) in an undergraduate program at the college or university where the intervention takes place\n3. Students who endorse some psychotic experiences (Peter's et al. Delusion Inventory (PDI) score \\> 3)\n\nExclusion criteria:\n\n1. Inability to provide informed consent\n2. Not proficient in English\n3. Current self-reported Diagnostic Statistical Manual 5 (DSM-5) diagnosis with active symptoms (such as active psychotic symptoms, current suicidality, serious active alcohol or substance use, marked deterioration in functioning over the prior month) determined by clinical interview with participant, or self-report of a psychiatric diagnosis that necessitates close monitoring or individual therapy and\u002For inpatient or partial hospitalization\n4. Current enrollment in psychological or behavioral health treatment.\n5. Current use of psychotropic medications (other than stimulants) prescribed by a physician.\n6. A diagnosis of a serious, chronic mental illness as determined by the Mini-International Neuropsychiatric Interview (MINI)","30 Years",{"count":436,"type":21},192,[131],"This is a randomized controlled trial testing the efficacy of Resilience Training in college students with elevated transdiagnostic risk for developing a serious mental illness.",[227,76,27],"2026-05-07",{"date":419,"type":39},{"date":443,"type":39},"2025-02-10",{"date":445,"type":21},"2029-06",{"name":150,"class":151},{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":15,"sex":16,"minAge":127,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":47},"100608551","quantifying-multi-step-avoidance-in-anxiety-100608551","NCT07203027","Quantifying Multi-step Avoidance in Anxiety","Quantifying Neural Signatures of Multi-step Avoidance Behavior in Anxiety","Inclusion Criteria:\n\n* Ability to comprehend written and spoken English\n* Ability to provide informed consent\n* Estimated intelligence quotient (IQ) \\>70.\n* Clinically significant anxiety symptoms (scoring above clinical cutoff on at least one Inventory of Depression and Anxiety Symptoms (IDAS) anxiety-related subscale and\u002For OASIS total)\n* Significant anxiety-related avoidance (scoring 2 or above on a 0-4 scale, indicating at least \"occasional\" avoidance) on the avoidance-related question on the Overall Anxiety Severity and Impairment Scale (OASIS)\n* Functional impairment, defined as at least moderate impairment in one WHO Disability Assessment Schedule (WHODAS 2.0) domain related to anxiety.\n\nExclusion Criteria:\n\n* Individuals younger than 22 or older than 55,\n* Individuals with an IQ \\\u003C 70,\n* A lifetime history of neurological disorder or brain damage,\n* Contraindications for undergoing MRI scanning,\n* A lifetime history or diagnosis of psychosis or bipolar disorder,\n* Current substance use intoxication or withdrawal,\n* Severe risk of suicide, or\n* Recent (\\\u003C3 months) changes in psychotropic medicine or psychotherapy treatment,\n* Ineligible at the PI's discretion, are excluded.","55 Years",{"count":456,"type":21},163,[131],"This study aims to learn more about avoidance behavior in people with anxiety, using mathematical models of decision-making processes and decoded neural signals of threat imminence.\n\nResearchers are investigating anxiety-related behavior and brain function in people with and without anxiety. Investigators are also looking at how behavior and brain function during tasks in the lab relate to avoidance in their daily lives. The investigators will also test whether changing how people avoid things in a behavioral task affects how people avoid things in their everyday life.",[82,27],[461,462],"Avoidance behavior","Fear learning","2026-05-05",{"date":440,"type":39},{"date":466,"type":21},"2027-01",{"date":468,"type":21},"2030-06",{"name":470,"class":151},"Emory University",{"id":472,"slug":473,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":18,"enrollmentInfo":478,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":92},"100595112","mindful-self-compassion-for-anxiety-and-depression-impact-of-delivery-method-100595112","NCT07028216","Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method","Mindful Self-Compassion for Anxiety and Depression: A Randomized Comparison of In-Person Versus Videoconference Delivery","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* Must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners",{"count":479,"type":21},80,[131],"The study will compare the delivery of an 8-week Mindful Self-Compassion training, in-person against video-conference, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder or dysthymia.",[27,483,484,485,486,28,487],"Generalized Anxiety Disorder","Social Anxiety Disorder","Panic Disorder","Agoraphobia","Persistent Depressive Disorder (Dysthymia)","2026-05-03",{"date":463,"type":39},{"date":491,"type":39},"2025-06-01",{"date":493,"type":21},"2027-08-31",{"name":495,"class":151},"Georgetown University",{"id":497,"slug":498,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":523,"locationsCount":92},"100640403","ai-guided-cbt-for-depression-and-anxiety-100640403","NCT07576686","AI-Guided CBT for Depression and Anxiety","The Significance of Artificial Intelligence-Guided Psychotherapy of Depression and Anxiety Disorders","AI-CBT-DA","Inclusion Criteria:\n\nAge 18 years or older Diagnosis of mild depressive disorder and\u002For anxiety disorder confirmed by a structured clinical interview (MINI) Ability to understand and provide informed consent Access to a device capable of using the digital platform (computer, tablet, or smartphone) Willingness to participate in weekly sessions over a 10-week period\n\nExclusion Criteria:\n\nModerate to severe depressive disorder Current or past diagnosis of psychotic disorder Bipolar disorder Substance use disorder or dependence Primary diagnosis of antisocial personality disorder Severe cognitive impairment or inability to use digital tools Acute suicidal risk requiring immediate intervention Concurrent participation in another structured psychotherapy program-",{"count":411,"type":21},[131],"This study aims to evaluate the effectiveness of an artificial intelligence (AI)-guided cognitive behavioral therapy (CBT) program for the treatment of mild depression and anxiety disorders in adults.\n\nDepression and anxiety disorders are among the most common mental health conditions worldwide and are associated with significant individual and societal burden. Despite the availability of effective treatments, access to psychotherapy remains limited due to insufficient resources and long waiting times. Digital mental health interventions, particularly those supported by artificial intelligence, have the potential to increase accessibility and scalability of evidence-based treatments.\n\nIn this controlled clinical trial, participants diagnosed with mild depressive disorder and\u002For anxiety disorders will be assigned to either an experimental group receiving AI-guided CBT or a control group receiving standard psychiatric care. The intervention will be delivered through a digital platform and will consist of structured weekly sessions over a 10-week period.\n\nThe primary objective of the study is to assess changes in symptoms of depression and anxiety. Secondary outcomes include perceived stress, social support, digital therapeutic alliance, and overall clinical improvement.\n\nThe findings of this study are expected to contribute to the understanding of the role of AI in psychotherapy and its potential to improve access to mental health care.",[508,27],"Depression - Major Depressive Disorder",[510,511,512,79,82,513,514,515,516],"AI-guided psychotherapy","Cognitive Behavioral Therapy","Digital Mental Health","Artificial Intelligence","Digital Therapeutic Alliance","eHealth","Internet-based CBT","2026-05-01",{"date":519,"type":39},"2026-05-08",{"date":521,"type":39},"2026-01-07",{"date":207,"type":21},{"name":524,"class":151},"Aleksandra Stojanovic",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":92},"100528580","pilot-effectiveness-trial-of-an-act-self-help-workbook-tailored-specifically-for-prisons-100528580","NCT06162624","Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons","Inclusion Criteria:\n\n* 18 years of age or older\n* Reading level of 6th grade or higher determined by the Wide Range Achievement Test\n* Moderate or severe anxiety and\u002For depression determined by the Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI)\n* No active self-harm or active suicidal intent\n* No scheduled transfer or release for at least three months\n* Must be willing and able to participate, including having permission and ability to use study materials, such as paper and a writing utensil\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Active self-harm or suicidal intent\n* Scheduled transfer or release within three months",{"count":532,"type":21},96,[131],"The goal of this research study is to adapt an ACT-self-help workbook to the prison setting and determine the feasibility acceptability, and effectiveness of this workbook.\n\nParticipants can expect to be in the study for 13 weeks.",[82,79,536,27],"Depression, Anxiety",[538],"incarcerated","2026-04-28",{"date":541,"type":39},"2026-05-04",{"date":543,"type":39},"2024-12-09",{"date":545,"type":21},"2026-09-30",{"name":547,"class":151},"University of Wisconsin, Madison",{"id":549,"slug":550,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":22,"phases":557,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":92},"100482975","efficacy-of-a-transdiagnostic-group-treatment-for-emotional-disorders-applied-in-blended-format-a-controlled-study-100482975","NCT05569018","Efficacy of a Transdiagnostic Group Treatment for Emotional Disorders Applied in Blended Format: a Controlled Study.","Efficacy of a Group Treatment Based on Transdiagnostic Perspective for Emotional Disorders and Applied in Blended Format: a Randomized Controlled Trial.","Inclusion Criteria:\n\n* Being 18 years old or more.\n* DSM-5 (APA, 1013) diagnostic criteria for emotional disorder (panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, major depressive disorder, dysthymia, obsessive-compulsive disorder, non-specified anxiety disorder, non-specified depressive disorder).\n* Good understanding of Spanish.\n* Access to the Internet and email address.\n* Informed consent to participate.\n\nExclusion Criteria:\n\n* Diagnosis of a severe mental disorder (psychotic disorder, bipolar disorder, substance and\u002For alcohol dependence).\n* High risk of suicide.\n* Having a serious medical illness or other condition that prevents treatment from being carried out.\n* Receiving another psychological treatment during the study period.\n* Changes and\u002For increases in pharmacological treatment during the study period (a decrease is accepted).",{"count":556,"type":21},144,[131],"This study will consist in a randomized controlled clinical trial (RCT) to test the efficacy of a blended group transversal protocol (BLGr-TP) compared to a face-to-face group transversal protocol (FFGr-TP).\n\nThe main aims of the study are the following:\n\n* To analyze the differential efficacy of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders in aspects of clinical measures, as well as in terms of retention and dropout rate and adherence.\n* To analyze the differential acceptability of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders.\n\nIn addition, it is intended to carry out a study of mediators and moderators of the efficacy of both interventions.\n\nThe established hypotheses in relation to the main goals are:\n\n* Both treatment modalities (FFGr-TP and BLGr-TP) will achieve improvements in the symptoms of emotional disorders, reflected in the scores of the clinical measures.\n* The BLGr-TP will show equivalent efficacy to the FFGr-TP.\n* The BLGr-TP will show an acceptability comparable to the face-to-face protocol. Both modalities will be well valued by the participants.\n* In both treatment modalities, the changes achieved are expected to be maintained over time (3, 6 and 12 months).",[27,560],"Depressive Disorders",[562,563,564,565,566],"Cognitive-Behavioral Therapy","Transdiagnostic CBT","Blended CBT","Group CBT","Emotional disorders",{"date":463,"type":39},{"date":569,"type":39},"2024-11-23",{"date":571,"type":21},"2027-07",{"name":573,"class":151},"Universitat Jaume I",{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":328,"enrollmentInfo":580,"targetDuration":4,"studyType":22,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":601},"100585148","enhancing-engagement-by-integrating-goals-and-concerns-that-matter-to-patients-100585148","NCT06898593","Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients","Inclusion Criteria:\n\n* Patients enrolled in the Collaborative Care Model (CoCM) at Dartmouth Health\n\nExclusion Criteria:\n\n* Patients not enrolled in the Collaborative Care Model (CoCM) at Dartmouth Health",{"count":581,"type":21},2448,[131],"The goal of this clinical trial is to learn if adding patients' goals and concerns to measurement-based collaborative care can tailor care and provide a more holistic view of treatment, thereby improving engagement in care among adult patients receiving collaborative care. The main questions it aims to answer are:\n\n* Does using a clinical decision support system (which includes an enhanced pre-visit questionnaire and patient-level dashboard) improve patient engagement in the collaborative care model?\n* Does using a clinical decision support system improve patient and clinician satisfaction with care?\n\nResearchers will compare the enhanced collaborative care with traditional collaborative care.\n\nPatient participants will complete pre-visit questionnaires before their collaborative care appointments. Responses will be viewed by the clinician and\u002For patient in a visual dashboard inside the electronic health record.",[27,585],"Depression Disorders",[587,588,589,590,79,82,591],"Collaborative Care Model","pre-visit questionnaire","dashboard","clinical decision support system","integrated behavioral health and primary care","2026-04-27",{"date":594,"type":39},"2026-04-29",{"date":596,"type":39},"2025-04-02",{"date":598,"type":21},"2028-07-31",{"name":600,"class":151},"Dartmouth-Hitchcock Medical Center",6,{"id":603,"slug":604,"hasResults":11,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":11,"sex":16,"minAge":609,"maxAge":159,"enrollmentInfo":610,"targetDuration":4,"studyType":22,"phases":612,"briefSummary":613,"conditions":614,"keywords":615,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":47},"100604114","personalized-digital-treatment-for-adolescent-anxiety-a-feasibility-trial-100604114","NCT07145307","Personalized Digital Treatment for Adolescent Anxiety: A Feasibility Trial","Evaluation of a Personalised Digital Treatment for Adolescents With Anxiety Disorders - A Feasibility Trial in Routine Care","Inclusion Criteria:\n\n* 13 to 18 years old\n* Adequate Norwegian reading, writing and speaking skills\n* Access to the internett and a smart-phone\n* Diagnosed anxiety disorder\n* Receiving outpatient treatment for their anxiety disorder\n* Exposure therapy included in therapy during the study period\n* Therapist agrees to incorporate the app as an ad-on to therapy\n* For patients receiving medication, inclusion requires a stable dose of medication for a psychiatric disorder for six weeks\n\nExclusion Criteria:\n\n* Participants with serious mental illness, such as suicidality or poor general functioning may be excluded if participation is considered unfeasible or potentially harmful. Decision will be based on collaborative evaluation by the participants therapist and the research-team.","13 Years",{"count":611,"type":21},46,[131],"The goal of this feasibility study is to test whether a new blended digital intervention for adolescents with anxiety disorders is feasible and acceptable for use, and to help plan future larger scale studies. The main questions it aims to answer are:\n\n* A: Can the investigators recruit appropriate participants?\n* B: How appropriate are the data collection procedures and outcome measures?\n* C: Are the study procedures and interventions suitable for and acceptable to the participants?\n* D: Does the research team have the resources and ability to manage the study and intervention?\n* E: Does the intervention show promise of being successful for adolescents with anxiety disorders?\n\nParticipants will:\n\n* Receive outpatient anxiety treatment, typically every other week or weekly.\n* Use the Sidekick app as a homework supplement to plan, carry out, and evaluate exposure exercises between treatment sessions.\n* Complete questionnaires before, during, after, and three months after using the app.\n* Some participants and therapists will be invited to take part in qualitative interviews following the intervention.",[27],[171,616,617,618,619,620,621,137,622],"digital interventions","digital cognitive behavioral therapy","digital ad-on","digital adjunct","adolescents","feasibility trial","mobile app","2026-04-22",{"date":539,"type":39},{"date":626,"type":39},"2025-10-20",{"date":628,"type":21},"2027-03",{"name":630,"class":631},"Helse Stavanger HF","OTHER_GOV",{"id":633,"slug":634,"hasResults":11,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":15,"sex":16,"minAge":639,"maxAge":409,"enrollmentInfo":640,"targetDuration":4,"studyType":22,"phases":641,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":92},"100521237","dino-rct---treating-anxiety-in-children-with-autism-100521237","NCT06066983","DINO RCT - Treating Anxiety in Children With Autism","Treating Anxiety in Young Children With Autism","Inclusion Criteria:\n\n* Age 4 years 0 months to 6 years 11 months\n* DSM-5 ASD diagnosis based on clinical impressions and results of the Autism Diagnostic Observation Schedule-2 (ADOS-2)\n* CBCL Anxiety Problems T-score \\> 65\n* SB-5 ABIQ \\> 60\n* Receptive and expressive language age equivalent \\> 36 months based on Test of Early Language Development, Fourth Edition (TELD-4)\n* Parent (or other caregiver) available and willing to attend 14-week intervention\n* Absence of identifiable neurological (e.g., epilepsy), genetic (e.g., Down syndrome, fragile X, tuberous sclerosis, neurofibromatosis) or severe sensory-motor (e.g., severe vision impairment) conditions\n* Able to walk independently (a requirement for ADOS-2)\n\nExclusion Criteria:\n\n* Primary language other than English\n* Child is in foster care\n* Child displays severe behavior challenges that prevent participation in treatment groups (i.e., severe tantrums, aggression, or self-injury)\n* Participating parent experiencing active symptoms of substance abuse or severe mental illness (i.e., schizophrenia, bipolar disorder)","4 Years",{"count":223,"type":21},[131],"Anxiety is prevalent in young children, under 7 years of age, with autism. Yet, few studies have examined anxiety interventions for this age range, and only one anxiety treatment study has included young children with cognitive and language delays. Anxiety treatment models utilizing cognitive-behavioral therapy (CBT), adapted for children with autism, are empirically supported in school-age autistic children. Further, preliminary evidence suggests CBT approaches may reduce intolerance of uncertainty (IU), a mechanistic construct that may contribute to the maintenance of anxiety in autistic children. This study seeks to address the existing gap in anxiety treatment by examining the feasibility and preliminary efficacy of a novel, telehealth CBT intervention, DINO Strategies for Anxiety and intolerance of Uncertainty Reduction (DINOSAUR), which targets both anxiety and IU in young autistic children.",[644,27],"Autism Spectrum Disorder",{"date":646,"type":39},"2026-04-23",{"date":648,"type":39},"2024-01-02",{"date":650,"type":21},"2026-10-15",{"name":652,"class":151},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",{"id":654,"slug":655,"hasResults":11,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":4,"enrollmentInfo":661,"targetDuration":4,"studyType":22,"phases":663,"briefSummary":664,"conditions":665,"keywords":667,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":92},"100611310","closed-loop-neurofeedback-targeting-the-right-dorsolateral-prefrontal-cortex-for-cardiac-autonomic-modulation-in-coronary-artery-disease-with-anxiety-100611310","NCT07238920","Closed-Loop Neurofeedback Targeting the Right Dorsolateral Prefrontal Cortex for Cardiac Autonomic Modulation in Coronary Artery Disease With Anxiety","Closed-Loop Neurofeedback Targeting the Right Dorsolateral Prefrontal Cortex for Cardiac Autonomic Modulation in Coronary Artery Disease With Anxiety - A Randomized, Sham-Controlled Trial","HEART-SET-1","Inclusion Criteria:\n\n* Age \\>18 years, any sex.\n* Right-handed, with resting heart rate between 60 and 100 beats per minute.\n* Confirmed diagnosis of CHD, defined as at least one of the following:\n\n  (i) positive stress test; (ii) documented myocardial infarction (MI) with electrocardiographic changes and concurrent elevation of creatine kinase MB isoenzyme or troponin; (iii) angiographically confirmed coronary atherosclerosis with ≥50% stenosis in at least one coronary artery.\n* Diagnosis of an anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n* Hamilton Anxiety Rating Scale (HAMA) score ≥16 and 17-item Hamilton Depression Rating Scale (HAMD-17) score ≤17.\n\nExclusion Criteria:\n\n* Acute unstable angina.\n* Severe congestive heart failure (New York Heart Association \\[NYHA\\] class IV).\n* Valvular heart disease.\n* History of atrial fibrillation.\n* Unstable blood pressure, defined as systolic blood pressure \\>180 mmHg or \\\u003C90 mmHg.\n* Pregnancy.\n* History of unstable medical conditions, including cerebrovascular disease, dementia, hyperthyroidism, pulmonary disease, or malignancy. These are assessed through medical history, electronic health records, physical examination, and ECG findings.\n* High risk of suicide or homicide.\n* Presence of other psychiatric disorders, including psychotic disorders, bipolar disorder, or active substance use disorders.\n* Use of psychotropic medication within 1 month prior to enrolment, to avoid potential interference with haemodynamic measurements.",{"count":662,"type":21},56,[131],"The goal of this clinical trial is to test whether real-time fNIRS-BCI neurofeedback targeting the right dorsolateral prefrontal cortex (right DLPFC), using active volitional control during a slow-wave auditory acoustic paradigm, can suppress cardiac sympathetic activity and improve autonomic regulation in right-handed patients with stable coronary heart disease (CHD) and comorbid DSM-5 anxiety.\n\nThe main questions it aims to answer are:\n\nDoes real neurofeedback, compared with sham, reduce baseline-corrected heart rate during the auditory stimulation window? Does real neurofeedback, compared with sham, increase HRV spectral power around 0.0167 Hz (1\u002F60 Hz) and produce stronger suppression of right DLPFC activation? Does suppression of right DLPFC activation mediate the effect of group assignment on heart rate?\n\nIf there is a comparison group: Researchers will compare the real neurofeedback group with the sham (non-contingent) feedback group, which uses identical audio and interface, to determine whether coupling feedback to right DLPFC activity yields autonomic benefits.\n\nParticipants will:\n\nComplete eligibility screening in cardiology and psychiatry and provide informed consent; baseline demographics, medical history, vital signs, and medications are recorded (HAMA\u002FHAMD used for eligibility only).\n\nUndergo a 3-day adaptation phase to practice active volitional self-regulation while viewing a real-time energy bar mapped to right DLPFC statistics; adaptation data are not analyzed for outcomes.\n\nAttend two formal sessions (Days 4-5), each with 15 blocks of 60 s (20 s rest + 40 s stimulus). The auditory stimulus is a 1 Hz amplitude-modulated pure tone at approximately 60 dB; 10-second white-noise bursts are randomly embedded within the 40-second window. During the stimulation period, participants receive real or sham feedback on right DLPFC activation and act to push the energy bar below an unlabeled threshold line using active volitional strategies.\n\nUndergo synchronous fNIRS (HbO) and 3-lead ECG (1,000 Hz) recording throughout; online processing and rendering performance metrics are logged; adverse events are monitored and managed per protocol.",[666,27],"Coronary Heart Disease (CHD)",[668,82,669,670],"Coronary heart disease","Neurofeedback","Heart rate variability","2026-04-21",{"date":623,"type":39},{"date":674,"type":39},"2025-11-19",{"date":676,"type":21},"2026-08-21",{"name":678,"class":151},"Shenyang Medical College"]